HITV Lab Corporate Profile

What We Do

HITV Laboratory Sdn Bhd, (part of the Hasumi International Pte Ltd Group), is the owner of HITV Lab which is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer.

HITV (Hasumi™ Immuno-Therapeutic Vaccine); developed by Dr. Kenichiro Hasumi, founder of Hasumi International Research Foundation, is an autologous (patient derived) active cell-based immunotherapy for patients suffering from late stage or metastatic cancer. Dr. Hasumi's protocol has been found to be highly effective when used in combination with radiotherapy, and is a source of hope for cancer patients who already have metastases (i.e the cancer has spread to other parts of the body).

HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV therapy in late stage cancer patients led by the University of Maryland, USA ( Project Name : “Autologous Dendritic Cells Derived From Peripheral Blood Mononuclear Cells Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4 (CellGenix); Administered Intratumoral”).

HITV1
HITV2